Growth inhibitory effect of lithium gammalinolenate on pancreatic cancer cell lines: The influence of albumin and iron

European Journal of Cancer

Volumn 34, Issue 1, 1998, Pages 188-192

  Ravichandran, D ^a   Cooper, A ^a   Johnson, C D ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cultured; Gamma linolenic acid; Pancreatic neoplasms; Tumour cells

Indexed keywords

ALBUMIN; FATTY ACID DERIVATIVE; IRON; LINOLENIC ACID; LITHIUM GAMMA LINOLENATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG UPTAKE; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL;

ALBUMINS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FERRIC COMPOUNDS; GAMMA-LINOLENIC ACID; HUMANS; LITHIUM COMPOUNDS; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0031938726     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00369-9     Document Type: Article

References (26)

1. Coeberg JWW. Summary and discussion of results. In Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T, Esteve J, eds. Survival of Cancer Patients in Europe. The Eurocare study. Lyon, IARC Scientific Publications No. 132, 1995, 447-463.
2. Cullinan S, Moertel CG, Wieand HS, et al. A phase 3 trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cisplatin. Cancer 1990, 65, 2207-2212.
3. Begin ME, Das UN, Ells G. Cytotoxic effects of essential fatty acids (EFA) in mixed cultures of normal and malignant human cells. Prog Lipid Res 1986, 25, 573-576.
4. Begin ME, Ells G, Das UN, Horrobin DF. Differential killing of human carcinoma cells supplemented with n-3 and n-d polyunsaturated fatty acids. J Natl Cancer Inst 1986, 77, 1053-1062.
5. Fearon KCH, Falconer JS, Ross JA, et al. An open label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinoleate. Anticancer Res 1996,16, 867-874.
6. Hayashi Y, Fukushima S, Hirata T, Kishimoto S, Katsuki T, Nakano M. Anticancer activity of free gamma linolenic acid on AH-109A rat hepatoma cells and the effect of serum albumin on anticancer activity of gamma linolenic acid in vitro. J Pharmacobio-Dyn 1990, 13, 705-711.
7. Hostmark AT, Lystad E. Growth inhibition of human hepatoma cells (HepG2) by polyunsaturated fatty acids, protection by albumin and vitamin E. Acta Physio! Scar.d 1992, 144, 83-88.
8. Begin ME, Ells G, Horrobin DF. Polj-unsaturated fatty acid induced cytotoxicity against tumour cells and its relationship to lipid peroxidation. J Natl Cancer Inst 1988, 80, 188-194.
9. Mengeaud V, Nano JL, Fournel S, Rampal P. Effects of eicosapentaenoic acid, gammalinolenic acid and prostaglandin El on three human colon carcinoma cell lines. Prostaglandins Leuk Essent Fatty Acids 1992, 47, 313-319.
10. Madhavi N, Das UN. Effect of n-d and n-3 fatty acids on the survival of vincristine sensitive and resistant human cervical carcinoma cells in vitro. Cancer Lett 1994, 84, 31-41.
11. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumour cell lines using a microculture tetrazolium assay. Cancer Res 1988, 48, 589-601.
12. Falconer JS, Ross JA, Fearon KCH, Hawkins RA, O'Riordain MG, Carter DC. Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br J Cancer 1994, 69, 826-832.
13. Pritchard GA, Jones DL, Mansel RE. Lipids in breast carcinogenesis. Br J Surg 1989, 76, 1069-1073.
14. van der Merve CF, Booyens J. Oral gamma linolenic acid in 21 patients with untreatable malignancy. An ongoing pilot open clinical trial. BrJClin Prac 1987, 41, 907-915.
15. Botha JH, Robinson KM, Leary WP. Parenteral gamma linolenic acid administration in nude mice bearing a range of human tumour xenografts. S Afr Med J 1983, 64, 11-12.
16. Ramchurren N, Botha JH, Robinson KM, Leary WP. Effects of gamma linolenic acid on murine cells in vitro and in vivo. S Afr MedJ 1985, 68, 795-798.
17. Booyens J, Koenig L. The effect of dietary supplementation with gamma-linolenic acid on the growth of induced tumours in rats. S Afr MedJ 1984, 65, 660-661.
18. Mclllmurray MB, Turkie W. Controlled trial of gamma linolenic acid in Duke's C colorectal cancer. BMJ 1987, 294, 1260.
19. van der Merwe CF, Booyens J, Joubert HF, van der Merwe CA. The effect of gamma-linolenic acid, an in vitro cytostatic substance contained in evening primrose oil, on primary liver cancer. A double-blind placebo controlled trial. Prostaglandins Leuk Essent Fatty Acids 1990, 40, 199-202.
20. Anel A, Naval J, Desportes P, Gonzalez B, Uriel J, Pineiro A. Increased cytotoxicity of polyunsaturated fatty acids on human tumoral B and T-cell lines compared with normal lymphocytes. Leukaemia 1992, 6, 680-688.
21. Spector AA. Plasma albumin as a lipoprotein. In Scanu AM, Spector AA, eds. Biochemistry and Biology of Plasma Lipoproteins. New York, Marcel Dekker, 1986, 247-279.
22. Peters T, Reed RG. Serum albumin as a transport protein. In Blauer G, Sund H, eds. Transport by Proteins. Berlin, Walter de Gruyter, 1978, 57-78.
23. Cantrill RC, Elis G, Chisholm K, Horrobin DF. Concentration dependent effect of iron on gamma-linolenic acid toxicity in ZR75-1 human breast tumour cells in culture. Cancer Lett 1993, 72, 99-102.
24. Takeda S, Horrobin DF, Manku M, Sim PG, Ells G, Simmons V. Lipid peroxidation in human breast cancer cells in response to gamma linolenic acid and iron. Anticancer Res 1992, 12, 329-334.
25. Gonzalez MJ, Schemmel RA, Gray JI, Dugan L, Sheffield LG, Welsch CW. Effect of dietary fat on growth of MCF-7 and MDA-MB231 human breast carcinomas in athymic nude mice: relationship between carcinoma growth and lipid peroxidation product levels. Carcinogenesis 1991, 12, 1231-1235.
26. Wells MS, Awad WM. Iron and heme metabolism. In Devlin TM, ed. Text Book of Biochemistry with Clinical Correlations. New York, John Wiley & Sons, 1986, 855-874.